Home>>Adrenomedullin (1-50) amide (rat) (trifluoroacetate salt)

Adrenomedullin (1-50) amide (rat) (trifluoroacetate salt)

Catalog No.GC42739

Adrenomedullin (1-50) is a peptide hormone with RNA expressed in rat adrenal glands, lung, kidney, heart, and spleen, as well as in the duodenum and submandibular glands.

Products are for research use only. Not for human use. We do not sell to patients.

Adrenomedullin (1-50) amide (rat) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
500μg
$385.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Adrenomedullin (1-50) is a peptide hormone with RNA expressed in rat adrenal glands, lung, kidney, heart, and spleen, as well as in the duodenum and submandibular glands. The rat amino acid sequence is similar to human adrenomedullin (1-52) but lacks two amino acids and contains six substitutions. Adrenomedullin (1-50) increases cAMP concentration in rat platelets (ED50 = 50 nM) and decreases mean blood pressure in anesthetized rats when administered at an intravenous dose of 1 nmol/kg. It reduces vascular hyperpermeability and increases survival in a rat model of α-toxin-induced septic shock. Adrenomedullin (1-50) also inhibits binding of human adrenomedullin to rat astrocytes in vitro (IC50 = 0.27 nM).

Reviews

Review for Adrenomedullin (1-50) amide (rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Adrenomedullin (1-50) amide (rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.